Get started
Author

Carina Frago

Observed names: C. Frago, Dr Carina Frago
Institution: Sanofi (France)
ORCID: 0000-0003-2450-6420
Observed ORCID: 0000-0003-2450-6420
OpenAlex ID: A5024014414
Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease
2015 · Sri Rezeki Hadinegoro, Jose Luis Arredondo-García, et al. · New England Journal of Medicine · 1,079
PDF
Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial
2014 · Maria Rosario Capeding, Ngoc Huu Tran, et al. · The Lancet · 974
Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy
2018 · Saranya Sridhar, Alexander Luedtke, et al. · New England Journal of Medicine · 788
PDF
Viral genetic diversity and protective efficacy of a tetravalent dengue vaccine in two phase 3 trials
2018 · Michal Juraska, Craig A. Magaret, et al. · Proceedings of the National Academy of Sciences · 82
PDF
Four-year safety follow-up of the tetravalent dengue vaccine efficacy randomized controlled trials in Asia and Latin America
2018 · J.L. Arredondo-García, S.R. Hadinegoro, et al. · Clinical Microbiology and Infection · 66
Symptomatic Dengue Disease in Five Southeast Asian Countries: Epidemiological Evidence from a Dengue Vaccine Trial
2016 · Joshua Nealon, Anne-Frieda Taurel, et al. · PLoS neglected tropical diseases · 49
PDF
Analysis of Hospitalized and Severe Dengue Cases Over the 6 years of Follow-up of the Tetravalent Dengue Vaccine (CYD-TDV) Efficacy Trials in Asia and Latin America
2021 · Rémi Forrat, Gustavo H Dayan, et al. · Clinical Infectious Diseases · 26
PDF
Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, parallel, randomised, modified double-blind, placebo-controlled trial
2023 · Gustavo H Dayan, Nadine Rouphael, et al. · The Lancet Respiratory Medicine · 25
PDF
Dengue seroprevalence: data from the clinical development of a tetravalent dengue vaccine in 14 countries (2005–2014)
2018 · Maïna L’Azou, Jade Assoukpa, et al. · Transactions of the Royal Society of Tropical Medicine and Hygiene · 23
PDF
Dengue Endemicity, Force of Infection, and Variation in Transmission Intensity in 13 Endemic Countries
2020 · Joshua Nealon, Alain Bouckenooghe, et al. · The Journal of Infectious Diseases · 22
PDF
Efficacy after 1 and 2 doses of CYD-TDV in dengue endemic areas by dengue serostatus
2020 · Gustavo H. Dayan, Edith Langevin, et al. · Vaccine · 20
PDF
Long-term immunogenicity and safety of tetravalent dengue vaccine (CYD-TDV) in healthy populations in Singapore and Vietnam: 4-year follow-up of randomized, controlled, phase II trials
2019 · Ngoc Huu Tran, Danaya Chansinghakul, et al. · Human Vaccines & Immunotherapeutics · 20
PDF
Assessment of the long-term efficacy of a dengue vaccine against symptomatic, virologically-confirmed dengue disease by baseline dengue serostatus
2020 · Gustavo H. Dayan, Edith Langevin, et al. · Vaccine · 18
PDF
Bridging Efficacy of a Tetravalent Dengue Vaccine from Children/Adolescents to Adults in Highly Endemic Countries Based on Neutralizing Antibody Response
2019 · Peter B. Gilbert, Ying Huang, et al. · American Journal of Tropical Medicine and Hygiene · 12
PDF
Immunogenicity and safety of a dengue vaccine given as a booster in Singapore: a randomized Phase II, placebo-controlled trial evaluating its effects 5–6 years after completion of the primary series
2019 · Juliana Park, Sophia Archuleta, et al. · Human Vaccines & Immunotherapeutics · 11
PDF
Associations of human leukocyte antigen with neutralizing antibody titers in a tetravalent dengue vaccine phase 2 efficacy trial in Thailand
2021 · Rasmi Thomas, Danaya Chansinghakul, et al. · Human Immunology · 9
PDF
Periods of high dengue transmission defined by rainfall do not impact efficacy of dengue vaccine in regions of endemic disease
2018 · Chloé Pasin, M. Elizabeth Halloran, et al. · PLoS ONE · 9
PDF
Evaluating the Test-Negative Design for COVID-19 Vaccine Effectiveness Using Randomized Trial Data
2025 · Leah I. B. Andrews, M. Elizabeth Halloran, et al. · JAMA Network Open · 6
PDF
Humoral and cellular immunogenicity and safety following a booster dose of a tetravalent dengue vaccine 5+ years after completion of the primary series in Singapore: 2-year follow-up of a randomized phase II, placebo-controlled trial
2021 · Juliana Park, Sophia Archuleta, et al. · Human Vaccines & Immunotherapeutics · 6
Resource Use and Costs of Dengue: Analysis of Data from Phase III Efficacy Studies of a Tetravalent Dengue Vaccine
2017 · Hanna El Fezzazi, Marie Branchu, et al. · American Journal of Tropical Medicine and Hygiene · 6
PDF
Noninferiority Study of Purified Vero Rabies Vaccine—Serum Free in 3-dose and 2-dose Preexposure Prophylaxis Regimens in Comparison With Licensed Rabies Vaccines
2024 · Kulkanya Chokephaibulkit, Catherine Huoi, et al. · Clinical Infectious Diseases · 4
Long-term safety follow-up of children from a randomized—controlled phase II b proof—of—concept efficacy study of the live, attenuated, tetravalent dengue vaccine (CYD—TDV) in Thailand
2019 · Danaya Chansinghakul, Kriengsak Limkittikul, et al. · Asian Pacific Journal of Tropical Medicine · 4
Immunogenicity and Safety of vYF, a Yellow Fever Vaccine — A Phase 2 Trial
2026 · Emmanuel Feroldi, Mark J. Mulligan, et al. · New England Journal of Medicine · 3
Corrigendum to: Dengue Endemicity, Force of Infection and Variation in Transmission Intensity From 13 Endemic Countries
2020 · Joshua Nealon, Alain Bouckenooghe, et al. · The Journal of Infectious Diseases · 3
PDF
Immunogenicity and Safety of a Quadrivalent Meningococcal Tetanus Toxoid-Conjugate Vaccine (MenACYW-TT) in Meningococcal Vaccine-Naïve Participants across a Broad Age Range (2–55 Years) in Japan: a Phase III Randomized Study
2023 · Osamu Matsuoka, Mugen Ujiie, et al. · Japanese Journal of Infectious Diseases · 2
PDF
Works count: 29
Citation count: 3,269
H-index: 13
I10-index: 15
Year
Topic
Type